- Home
- BDTX vs ASMB Comparison
BDTX vs ASMB Comparison
Compare BDTX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- ASMB
- Stock Information
- Founded
- BDTX 2014
- ASMB 2005
- Country
- BDTX United States
- ASMB United States
- Employees
- BDTX N/A
- ASMB N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- BDTX Health Care
- ASMB Health Care
- Exchange
- BDTX Nasdaq
- ASMB Nasdaq
- Market Cap
- BDTX 132.5M
- ASMB 130.2M
- IPO Year
- BDTX 2020
- ASMB 2010
- Fundamental
- Price
- BDTX $2.58
- ASMB $18.14
- Analyst Decision
- BDTX Strong Buy
- ASMB Strong Buy
- Analyst Count
- BDTX 6
- ASMB 3
- Target Price
- BDTX $14.83
- ASMB $33.00
- AVG Volume (30 Days)
- BDTX 1.3M
- ASMB 41.3K
- Earning Date
- BDTX 08-05-2025
- ASMB 08-07-2025
- Dividend Yield
- BDTX N/A
- ASMB N/A
- EPS Growth
- BDTX N/A
- ASMB N/A
- EPS
- BDTX 0.09
- ASMB N/A
- Revenue
- BDTX $70,000,000.00
- ASMB $32,154,000.00
- Revenue This Year
- BDTX N/A
- ASMB $0.04
- Revenue Next Year
- BDTX N/A
- ASMB N/A
- P/E Ratio
- BDTX $29.29
- ASMB N/A
- Revenue Growth
- BDTX N/A
- ASMB 148.33
- 52 Week Low
- BDTX $1.20
- ASMB $7.75
- 52 Week High
- BDTX $6.75
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- BDTX 60.64
- ASMB 68.18
- Support Level
- BDTX $2.43
- ASMB $17.45
- Resistance Level
- BDTX $2.72
- ASMB $18.92
- Average True Range (ATR)
- BDTX 0.18
- ASMB 0.87
- MACD
- BDTX -0.00
- ASMB -0.05
- Stochastic Oscillator
- BDTX 76.11
- ASMB 74.68
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.